IL-SEVAN
27.10.2021 15:02:16 CEST | Business Wire | Press release
Sevan Multi-Site Solutions, Inc. (Sevan) has positively impacted millions of lives worldwide through the implementation of customized, end-to-end turnkey solutions for 28,000 retail healthcare client sites.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005377/en/
Sevan — a global leader in innovative design, program management, construction services and data analytics — extends services to pharmacies, COVID testing centers, hospitals, wellness clinics, kidney dialysis centers, veterinary clinics, tele-med centers and dental facilities for varying clients ranging from small businesses to Fortune 100 companies.
“It is an honor to prioritize the healthcare needs of our population and deliver world class solutions for our clients that impact and simplify life for us all daily,” said Jim Evans, Sevan’s CEO and President. “The definition of healthcare is evolving, and many around the globe are doing everything we can to strengthen offerings for people’s growing needs. Hats off to all who are amplifying retail healthcare spaces—it’s a privilege to celebrate this milestone with our great clients, team, partners and everyone involved.”
Sevan’s customized, end-to-end turnkey solutions for some of the largest retail and restaurant brands across the United States, Canada and the United Kingdom have totaled more than 35 million square feet in client site touches.
Sevan offers multi-site solutions for clients along entire project life cycles including Technology & Data Analytics, Real Estate & Development Services, Civil Zoning & Permitting, Surveys & Facility Assessments, Architecture & Engineering, Construction Services and Program Management.
“It has been an immense pleasure to collaborate with our healthcare clients as they push forward with serving our nation’s immediate and long-term health needs,” said Jim Furis, Sevan’s Chief Revenue Officer. “Their combined passion, initiative and creativity in pursuing new business models, delivering healthcare to underserved markets or making it easier to fill a prescription impacts the lives of millions. We are proud to be part of transforming their locations to help so many do fantastic work!”
In 2021, Sevan was recognized as an Employee-Rated Great Place to Work® for the eighth consecutive year and ranked on the Inc. 5000 list of the nation’s fastest-growing private companies for the fourth consecutive year. Also in 2021, Sevan ranked No. 21 on Engineering News-Record (ENR)’s Top 50 Program Management Firms and No. 44 on ENR’s Top 100 Construction Management-for-Fee Firms. In 2020, Sevan ranked No. 124 on the Financial Times FT 1000 list of America’s Fastest-Growing Companies. Visit our website to learn more about Sevan, our 2021 award rankings and acquisitions .
About Sevan
Sevan helps iconic, global brands optimize their multi-site construction and facility programs in the U.S. and internationally. Sevan is headquartered near Chicago in Downers Grove, Illinois, with 400+ employees and has an international office in London.
The vision of Sevan Multi-Site Solutions is to be the best in the world at delivering innovative design, program management, construction services and data analytics to organizations with multiple sites. Sevan has a passion for sustaining people, the environment and its clients’ businesses. Sevan helps iconic global brands, including 7-Eleven, AAFES, Albertsons, Amtrak, BP, Chipotle, Corvias, DaVita, HCA Healthcare, HEB, Jiffy Lube, Kroger, Luxottica, McDonald’s, Office Depot, QDOBA, Starbucks, Sunoco, Walgreens Boots Alliance, Walmart, WOW Carwash, Yum! Brands and Zaxby’s. Sevan rolls out multi-site initiatives efficiently, predictably and transparently. Applying breakthrough technology solutions, Sevan optimizes construction of new builds, rebuilds, remodels and renovations. Sevan has licensed architects in 49 states as well as D.C., Canadian provinces, Guam and the Northern Mariana Islands. Sevan has professional engineers on staff and general contractor licenses in more than 25 states. Since Sevan’s inception in 2011, the team has refreshed more than 21,000 retail stores and 14,000 restaurants. The team has also completed more than 28,000 surveys, totaling more than 700 million square feet. Sevan Elevate, a program that reinforces and continuously improves safety and sustainability across the company, is designed to impactfully deliver excellence to Sevan’s people and clients. To read more about Sevan, visit www.sevansolutions.com .
For more information, please contact Hafsa Mahmood by calling 312.285.0590 or via email at hafsa.mahmood@sevansolutions.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005377/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom